Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387392771> ?p ?o ?g. }
- W4387392771 abstract "Type 2 diabetes mellitus (T2DM) is a relevant risk factor for severe forms of COVID-19 (SARS coronavrus 2 [SARS-CoV-2] disease 2019), and calls for caution because of the high prevalence of T2DM worldwide and the high mortality rates observed in patients with T2DM who are infected with SARS-CoV-2. People with T2DM often take dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon-like peptide-1 receptor agonists (GLP-1ras), or sodium-glucose co-transporter-2 inhibitors (SGLT-2is), all of which have clear anti-inflammatory effects. The study aimed to compare (i) the severity and duration of hospital stay between patients with T2DM categorized by pre-hospitalization drug class utilization and (ii) the COVID-19-related death rates of those three groups. We designed an observational, retrospective, multi-center, population-based study and extracted the hospital admission data from the health care records of 1916 T2DM patients over 18 years old who were previously on GLP-1ra, SGLT-2i, or DPP-4i monotherapy and were hospitalized for COVID-19 (diagnosis based on ICD.9/10 codes) between January 2020 and December 2021 in 14 hospitals throughout Italy. We analyzed general data, pre-admission treatment schedules, date of admission or transfer to the intensive care unit (ICU) (i.e., the index date; taken as a marker of increased COVID-19 disease severity), and death (if it had occurred). Statistics analyzed the impact of drug classes on in-hospital mortality using propensity score logistic regressions for (i) those admitted to intensive care and (ii) those not admitted to intensive care, with a random match procedure used to generate a 1:1 comparison without diabetes cohort replacement for each drug therapy group by applying the nearest neighbor method. After propensity score matching, we checked the balance achieved across selected variables if a balance was ever achieved. We then used propensity score matching between the three drug classes to assemble a sample in which each patient receiving an SGLT-2i was matched to one on a GLP-1ra, and each patient on a DPP-4i was matched to one on a GLP-1ra, adjusting for covariates. We finally used GLP-1ras as references in the logistic regression. The overall mortality rate (MR) of the patients was 14.29%. The MR in patients with COVID was 53.62%, and it was as high as 42.42% in the case of associated T2DM, regardless of any glucose-lowering therapy. In those on DPP-4is, there was excess mortality; in those treated with GLP-1ras and SGLT-2is, the death rate was significantly lower, i.e., almost a quarter of the overall mortality observed in COVID-19 patients with T2DM. Indeed, the odds ratio (OR) in the logistic regression resulted in an extremely high risk of in-hospital death in individuals previously treated with DPP-4is [incidence rate (IR) 4.02, 95% confidence interval (CI) 2.2–5.7) and only a slight, nonsignificantly higher risk in those previously treated with SGLT-2is (IR 1.42, 95% CI 0.6–2.1) compared to those on GLP-1ras. Moreover, the longer the stay, the higher the death rate, which ranged from 22.3% for ≤ 3-day stays to 40.3% for 4- to 14-day stays (p < 0.01 vs. the former) and 77.4% for over-14-day stays (p < 0.001 vs. both the others). Our data do not support a protective role of DPP-4is; indeed, this role has already been questioned due to previous observations. However, the data do show a strong protective effect of SGLT-2is and GLP-1ras. Beyond lowering circulating glucose levels, those two drug classes were found to exert marked anti-phlogistic effects: SGLT-2is increased adiponectin and reduced urate, leptin, and insulin concentrations, thus positively affecting overall low-grade inflammation, and GLP-1ras may also greatly help at the lung tissue level, meaning that their extra-glycemic effects extend well beyond those acknowledged in the cardiovascular and renal fields. The aforedescribed observational clinical data relating to a population of Italian inpatients with T2DM suggest that GLP-1ras and SGLT-2is can be considered antidiabetic drugs of choice against COVID-19, and might even prove beneficial in the event of any upcoming pandemic that has life-threatening effects on the pulmonary and cardiovascular systems." @default.
- W4387392771 created "2023-10-07" @default.
- W4387392771 creator A5003557683 @default.
- W4387392771 creator A5011666802 @default.
- W4387392771 creator A5011766524 @default.
- W4387392771 creator A5025564910 @default.
- W4387392771 creator A5027787216 @default.
- W4387392771 creator A5033088264 @default.
- W4387392771 creator A5042464990 @default.
- W4387392771 creator A5057598608 @default.
- W4387392771 creator A5075307122 @default.
- W4387392771 creator A5081878436 @default.
- W4387392771 creator A5084852125 @default.
- W4387392771 date "2023-10-06" @default.
- W4387392771 modified "2023-10-09" @default.
- W4387392771 title "Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy" @default.
- W4387392771 cites W2027990537 @default.
- W4387392771 cites W2030809658 @default.
- W4387392771 cites W2091671824 @default.
- W4387392771 cites W2098083442 @default.
- W4387392771 cites W2119111857 @default.
- W4387392771 cites W2153042980 @default.
- W4387392771 cites W2163660677 @default.
- W4387392771 cites W2165037395 @default.
- W4387392771 cites W2306319461 @default.
- W4387392771 cites W2554228598 @default.
- W4387392771 cites W2614462090 @default.
- W4387392771 cites W2619744261 @default.
- W4387392771 cites W2737659318 @default.
- W4387392771 cites W2790286202 @default.
- W4387392771 cites W2790984670 @default.
- W4387392771 cites W2892498615 @default.
- W4387392771 cites W2900848270 @default.
- W4387392771 cites W3004318991 @default.
- W4387392771 cites W3014294089 @default.
- W4387392771 cites W3026368894 @default.
- W4387392771 cites W3043192034 @default.
- W4387392771 cites W3047144258 @default.
- W4387392771 cites W3047193933 @default.
- W4387392771 cites W3047781461 @default.
- W4387392771 cites W3048686971 @default.
- W4387392771 cites W3103267577 @default.
- W4387392771 cites W3109186718 @default.
- W4387392771 cites W3126003241 @default.
- W4387392771 cites W3126323226 @default.
- W4387392771 cites W3131618568 @default.
- W4387392771 cites W3132543947 @default.
- W4387392771 cites W3145758329 @default.
- W4387392771 cites W3145816854 @default.
- W4387392771 cites W3150712004 @default.
- W4387392771 cites W3170966862 @default.
- W4387392771 cites W3183300604 @default.
- W4387392771 cites W3189416067 @default.
- W4387392771 cites W3200885365 @default.
- W4387392771 cites W3203752952 @default.
- W4387392771 cites W4200017511 @default.
- W4387392771 cites W4200021172 @default.
- W4387392771 cites W4200439235 @default.
- W4387392771 cites W4213149093 @default.
- W4387392771 cites W4220971686 @default.
- W4387392771 cites W4225320779 @default.
- W4387392771 cites W4281795629 @default.
- W4387392771 cites W4293072321 @default.
- W4387392771 cites W4311271637 @default.
- W4387392771 doi "https://doi.org/10.1007/s13300-023-01472-8" @default.
- W4387392771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37801224" @default.
- W4387392771 hasPublicationYear "2023" @default.
- W4387392771 type Work @default.
- W4387392771 citedByCount "0" @default.
- W4387392771 crossrefType "journal-article" @default.
- W4387392771 hasAuthorship W4387392771A5003557683 @default.
- W4387392771 hasAuthorship W4387392771A5011666802 @default.
- W4387392771 hasAuthorship W4387392771A5011766524 @default.
- W4387392771 hasAuthorship W4387392771A5025564910 @default.
- W4387392771 hasAuthorship W4387392771A5027787216 @default.
- W4387392771 hasAuthorship W4387392771A5033088264 @default.
- W4387392771 hasAuthorship W4387392771A5042464990 @default.
- W4387392771 hasAuthorship W4387392771A5057598608 @default.
- W4387392771 hasAuthorship W4387392771A5075307122 @default.
- W4387392771 hasAuthorship W4387392771A5081878436 @default.
- W4387392771 hasAuthorship W4387392771A5084852125 @default.
- W4387392771 hasBestOaLocation W43873927711 @default.
- W4387392771 hasConcept C126322002 @default.
- W4387392771 hasConcept C134018914 @default.
- W4387392771 hasConcept C167135981 @default.
- W4387392771 hasConcept C177713679 @default.
- W4387392771 hasConcept C194828623 @default.
- W4387392771 hasConcept C2776376669 @default.
- W4387392771 hasConcept C2777180221 @default.
- W4387392771 hasConcept C2778763485 @default.
- W4387392771 hasConcept C2908647359 @default.
- W4387392771 hasConcept C555293320 @default.
- W4387392771 hasConcept C71924100 @default.
- W4387392771 hasConcept C99454951 @default.
- W4387392771 hasConceptScore W4387392771C126322002 @default.
- W4387392771 hasConceptScore W4387392771C134018914 @default.
- W4387392771 hasConceptScore W4387392771C167135981 @default.
- W4387392771 hasConceptScore W4387392771C177713679 @default.
- W4387392771 hasConceptScore W4387392771C194828623 @default.
- W4387392771 hasConceptScore W4387392771C2776376669 @default.